New Anti-Opioid Dosage Approved
The FDA approved a new dosage for sublingual Cassipa (buprenorphine and naloxone) for the maintenance treatment of opioid addiction.
The new approved dose consists of 16 mg of buprenorphine and 4 mg of naloxone. Buprenorphine reduces opioid cravings while naloxone helps reverse the effects of opioids.
FDA Commissioner Scott Gottlieb said the agency is “working to address the unfortunate stigma that’s sometimes associated with the use of opioid replacement therapy as one approach to the successful treatment of addiction.”
Teva Pharmaceuticals holds the marketing license for Cassipa.